CASI Pharmaceuticals - CASI Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI shares.
View CASI analyst ratings or view top-rated stocks.

2 brokerages have issued 1 year price targets for CASI Pharmaceuticals' shares. Their CASI share price forecasts range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 387.8% from the stock's current price.
View analysts price targets for CASI or view top-rated stocks among Wall Street analysts.

CASI Pharmaceuticals' stock was trading at $1.79 at the beginning of 2023. Since then, CASI stock has increased by 14.5% and is now trading at $2.05.
View the best growth stocks for 2023 here.

CASI Pharmaceuticals saw a drop in short interest in January. As of January 15th, there was short interest totaling 277,800 shares, a drop of 5.9% from the December 31st total of 295,200 shares. Based on an average daily volume of 33,900 shares, the days-to-cover ratio is presently 8.2 days. Approximately 2.1% of the shares of the company are short sold.
View CASI Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our CASI earnings forecast.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) released its quarterly earnings data on Monday, November, 14th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.13. The biotechnology company had revenue of $10.21 million for the quarter, compared to analysts' expectations of $10.40 million. CASI Pharmaceuticals had a negative net margin of 73.17% and a negative trailing twelve-month return on equity of 37.59%.

Shares of CASI Pharmaceuticals reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Blockchain (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

CASI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James Huang, Larry Zhang, Weihao Xu and Wei-Wu He.
View institutional ownership trends.

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CASI stock can currently be purchased for approximately $2.05.

CASI Pharmaceuticals (NASDAQ:CASI) has a market capitalization of $27.90 million and generates $30.17 million in revenue each year. The biotechnology company earns $-36,650,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis.

The company employs 176 workers across the globe.

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The official website for the company is www.casipharmaceuticals.com. The biotechnology company can be reached via phone at (240) 864-2600, via email at ir@casipharmaceuticals.com, or via fax at 301-315-2437.